Study of the Efficacy and Safety of IBI319 in Patients With Advanced Malignant Tumors

NCT04708210 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

256

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Malignant Tumors

Interventions

DRUG: IBI319

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.